CORDIS proporciona enlaces a los documentos públicos y las publicaciones de los proyectos de los programas marco HORIZONTE.
Los enlaces a los documentos y las publicaciones de los proyectos del Séptimo Programa Marco, así como los enlaces a algunos tipos de resultados específicos, como conjuntos de datos y «software», se obtienen dinámicamente de OpenAIRE .
Resultado final
This deliverable will outline the procedures for risk monitoring and evaluation throughout the project and include a risk register.
Evaluation of immunogenicity of all candidates (se abrirá en una nueva ventana)All vaccine candidates have been evaluated and if working, also tested for immunogenicity in mouse and rabbit studies. The samples have been analyzed.
Screening of sera from human vacinees by in vitro neutralization (se abrirá en una nueva ventana)Completed analysis of human sera obtained from the vaccinated healthy volunteers in the phase I clinical trial to neutralize SARS-COV-2 in cell culture.
Interim Activity Report (se abrirá en una nueva ventana)Delivery of Interim Activity report for Month 1-6
Synthesis of vaccine candidates, proteins and peptides (se abrirá en una nueva ventana)All vaccine candidates, proteins and produced and delivered to KI
Results from vaccine and challenge study (se abrirá en una nueva ventana)Completed analysis of protection studies in mice were immunized mice have been challenged with SARS-COV-2. This assists in the selection of the vaccine candidate.
Documentation for EMA (se abrirá en una nueva ventana)Provide complete documentation of the Cliniporator to the EMA/MPA for use in delivery of plasmid DNA vaccines in humans
GMP manufactured aseptically filled plasmid drug product (se abrirá en una nueva ventana)Dispensing of the vaccine candidate
QC tested and QP released GMP plasmid drug product (se abrirá en una nueva ventana)QC tested and QP released GMP produced vaccine candidate
Protocol for neutralization assay (se abrirá en una nueva ventana)Established assay for determination of neutralizing antibodies to SARS-COV-2 that can be used to test mouse and rabbit sera
Summarizing stability data report(s) for BDS (se abrirá en una nueva ventana)Report that describes the long term stability of the vaccine candidate
Selection of the best vaccine candidate for GMP and tox studies (se abrirá en una nueva ventana)One vaccine candidate has been selected based on safety and immunogenicity for production according to GMP and GLP toxicology testing.
Study plan for the GLP toxicity study (se abrirá en una nueva ventana)Written plan with the design of the toxocological study of the vaccine candidate
Manufactured GMP grade bulk drug substance pDNA (se abrirá en una nueva ventana)Production of a GMP grade bulk drug substance of the vaccine candidate
QC tested and QP released GMP drug substance (se abrirá en una nueva ventana)Release of a GMP produced vaccine candidate
A single step delivery procedure (se abrirá en una nueva ventana)Develop a device that is added to the Cliniporation electrode handle that enables injection of DNA and in vivo electroporation in a single step. This may or may not be used in the clinical trial depending on requirements from the EMA/MPA.
Communication and Dissemination Plan (se abrirá en una nueva ventana)Establish a Communication and Dissemination Plan
Optimization of selected vaccine candidates to further avoid a cytokine storm (se abrirá en una nueva ventana)ORF mutants of vaccine candidates that lost the ability to activate pro-inflammatory responses
Assays to measure cytokine induction and IFN supression (se abrirá en una nueva ventana)Primers, RT-qPCR assays, transfection protocols, control constructs, transfection protocols, reporter assays
Report writing for the IMPD, month (se abrirá en una nueva ventana)A written report of the toxicological evaluation of the vaccine candidate according to GLPto be submitted to EMAMPA
Midterm recruitment report (se abrirá en una nueva ventana)Approvals from ethics committee and EMA/MPA for phase I clinical trial (se abrirá en una nueva ventana)
Completed clinical trial in humans and writing of report (se abrirá en una nueva ventana)
Summarizing stability data report(s) for plasmid drug product (se abrirá en una nueva ventana)
Written reports on the stability of the GMP produced vaccine candidate
Pre-Production Evaluation and plasmid production for toxicology studies (se abrirá en una nueva ventana)Complete study report on the manufacturing system performance and plasmid production for toxicological evaluation.
Consortium secured intranet and Management handbook (se abrirá en una nueva ventana)These tools will facilitate communication and establish the principles of work within the consortium. The Management Handbook will contain all internal consortium agreement related rules (for publication, etc.), key contact and info to use the intranet, plus a “digest” of H2020 rules easier to understand for SMEs and advices adapted to the consortium.
Manufactured and QP released Master Cell Bank (se abrirá en una nueva ventana)Generation of a Master cell bank for the vaccine and QP release
A locked Cliniporator with pulse pattern for plasmid DNA delivery (se abrirá en una nueva ventana)Establishment of a pulse pattern for in vivo electroporation that is optimized for delivery of plasmid DNA
Assessment of cytokine induction and IFN suppression by first set of vaccine candidates (se abrirá en una nueva ventana)Statistically robust data on upregulation of IFN-beta, IFN-lambda 1 and 2, IL-6, IL-8, TNF-alpha, CCL4, CCL5, CXCL10. Statistically robust data on dysregulation of IFN-beta induction or IFN signaling
Evaluation of the management tools and procedure (se abrirá en una nueva ventana)This document will outline the outcomes of the internal evaluation of the management tools and procedures put in place in OPENCORONA including recommendations for future improvements.
Completion of the GLP toxicity study, month (se abrirá en una nueva ventana)Completed toxicological evaluation according to GLP of the vaccine candidate
Optimization selected vaccine candidates to further avoid of suppression of IFN induction (se abrirá en una nueva ventana)ORF mutants of vaccine candidates that lost the ability to suppress IFN induction
Challenge protocol (se abrirá en una nueva ventana)Established protocol for infecting mice with SARS-COV-2 before or completed vaccinations
External Project Website launch.
Publicaciones
Autores:
Sofia Appelberg
Gustaf Ahlén
Jingyi Yan
Negin Nikouyan
Sofie Weber
Olivia Larsson
Urban Höglund
Soo Aleman
Friedemann Weber
Emma Perlhamre
Johanna Apro
Eva-Karin Gidlund
Ola Tuvesson
Simona Salati
Matteo Cadossi
Hanna Tegel
Sophia Hober
Lars Frelin
Ali Mirazimi
Matti Sällberg
Publicado en:
EMBO Molecular Medicine, 2022, ISSN 1757-4684
Editor:
EMBO Press
DOI:
10.15252/emmm.202215821
Autores:
Ulrike Felgenhauer, Andreas Schoen, Hans Henrik Gad, Rune Hartmann, Andreas R. Schaubmar, Klaus Failing, Christian Drosten, Friedemann Weber
Publicado en:
Journal of Biological Chemistry, Edición 295/41, 2020, Página(s) 13958-13964, ISSN 0021-9258
Editor:
American Society for Biochemistry and Molecular Biology Inc.
DOI:
10.1074/jbc.ac120.013788
Autores:
Jingyi Yan
Chandrashekar Ravenna Bangalore
Negin Nikouyan
Sofia Appelberg
Daniela Nacimento Silva
Haidong Yao
Anna Pasetto
Friedemann Weber
Sofie Weber
Olivia Larsson
Urban Höglund
Gordana Bogdanovic
Malin Grabbe
Soo Aleman
Laszlo Szekely
Attila Szakos
Ola Tuvesson
Eva-Karin Gidlund
Matteo Cadossi
Simona Salati
Matti Sällberg
Publicado en:
Molecular Therapy, Edición Volume 32, Edición 2, 7 February 2024, 2024, Página(s) Pages 540-555, ISSN 1525-0016
Editor:
Nature Publishing Group
DOI:
10.1016/j.ymthe.2024.01.007
Autores:
Gustaf Ahlén, Lars Frelin, Negin Nikouyan, Friedemann Weber, Urban Höglund, Olivia Larsson, Marie Westman, Ola Tuvesson, Eva-karin Gidlund, Matteo Cadossi, Sofia Appelberg, Ali Mirazimi, Matti Sällberg
Publicado en:
Journal of Virology, Edición 94/18, 2020, ISSN 0022-538X
Editor:
American Society for Microbiology
DOI:
10.1128/jvi.01279-20
Autores:
Natalie Frese, Patrick Schmerer, Martin Wortmann, Matthias Schürmann, Matthias König, Michael Westphal, Friedemann Weber, Holger Sudhoff, Armin Gölzhäuser
Publicado en:
Beilstein Journal of Nanotechnology, Edición 12, 2021, Página(s) 172-179, ISSN 2190-4286
Editor:
Beilstein-Institut Zur Forderung der Chemischen Wissenschaften
DOI:
10.3762/bjnano.12.13
Buscando datos de OpenAIRE...
Se ha producido un error en la búsqueda de datos de OpenAIRE
No hay resultados disponibles